All In Biotech

Drug Trial Radar · NCT04726592

Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Last checked: Nov 20, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. Randomized with 323 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

323

Actual

Start

Jul 8, 2021

Primary completion

Apr 10, 2024

Study completion Apr 10, 2024

Sponsor

Lead sponsor
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of clorazepate in addition to the usual medication for treating migraine attack in the emergency room

Conditions

  • Migraine
  • Migraine Without Aura
  • Migraine With Aura
  • Headache

Interventions

  • Clorazepate DipotassiumDrug

    Clorazepate Dipotassium : 20 mg intravenous injection

  • PlaceboDrug

    Placebo IV

  • KetoprofenDrug

    Ketoprofen 100 mg IV

  • MetoclopramideDrug

    Metoclopramide 10 mg IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pain reliefTime frame: 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hôpital Lariboisière

    Paris, Île-de-France Region, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.